Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Ozempic is under clinical development by Novo Nordisk and currently in Phase III for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...

Denmark's drug regulator asks EMA to investigate potential link between Novo Nordisk's diabetes drug Ozempic and rare eye ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...